
Opinion|Videos|March 29, 2024
Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
Author(s)Rebecca A. Shatsky, MD
A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5





























